Revolution Medicines (RVMD) EBIT Margin (2019 - 2025)
Historic EBIT Margin for Revolution Medicines (RVMD) over the last 6 years, with Q3 2025 value amounting to 2758.74%.
- Revolution Medicines' EBIT Margin changed N/A to 2758.74% in Q3 2025 from the same period last year, while for Sep 2025 it was 9074.67%, marking a year-over-year increase of 971066100.0%. This contributed to the annual value of 4207.12% for FY2023, which is 34771100.0% down from last year.
- According to the latest figures from Q3 2025, Revolution Medicines' EBIT Margin is 2758.74%.
- In the past 5 years, Revolution Medicines' EBIT Margin ranged from a high of 2758.74% in Q3 2025 and a low of 24256.47% during Q4 2023
- Over the past 4 years, Revolution Medicines' median EBIT Margin value was 722.9% (recorded in 2022), while the average stood at 2984.36%.
- Its EBIT Margin has fluctuated over the past 5 years, first surged by 25481300bps in 2022, then crashed by -238539400bps in 2023.
- Quarter analysis of 4 years shows Revolution Medicines' EBIT Margin stood at 559.33% in 2021, then rose by 28bps to 402.52% in 2022, then crashed by -5926bps to 24256.47% in 2023, then soared by 111bps to 2758.74% in 2025.
- Its EBIT Margin stands at 2758.74% for Q3 2025, versus 24256.47% for Q4 2023 and 2845.11% for Q2 2023.